The NCI-designated Dana-Farber/Harvard Cancer Center (DF/HCC).includes the Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and the Beth Israel Deaconess Medical Center (BIDMC) and functions in overseeing all aspects of clinical trials performed at these sites. The overall objective of this UM1 Cooperative Agreement application from the DF/HCC, which serves as the Lead Academic Organization (LAO), is to provide the clinical and scientific expertise and patient resources to participate in the integrated NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN). The DF/HCC Translational Pharmacology and Early Therapeutic Trials (TPETT) Program has coordinated early phase drug development efforts at DF/HCC with support under an.NCI/CTEP Phase I U01 Agreement in place since 1993. During the current funding period (2/1/2008-present), members of the DF/HCC TPETT Program have participated in the conduct of 48 CTEP-sponsored trials with an overall accrual of 470 patients (85/year). The DF/HCC has also collaborated with other U01 sites, such as MSKCC, MDACC and Karmanos Cancer Institute, in the performance of CTEP trials. The DF/HCC ET-CTN site will consist of a Leadership and Steering Committee that will oversee regulatory, pharmacokinetic, genomic, pathology-based, biostatistical, and career development components. DF/HCC will be committed to the formation of investigational agent-specific trans-network Project Teams with the NCI and other ET-CTN sites to define drug development plans and conduct early phase therapeutic trials of CTEP-sponsored agents. Expertise of the DF/HCC ET-CTN in pharmacokinetics, pharmacodynamics, cancer biology, biomarker assay development, imaging and molecular characterizations will be shared with other sites in team-based approaches. Emphasis will also be placed on mentored training of junior investigators in experimental therapeutics.

Public Health Relevance

The importance of this work to (the) public health is realized by the need for improved treatment options for the substantial number of patients with (advanced) cancer unresponsive to existing treatments, who are candidates for new investigational agents. The research proposed in this UM1 Cooperative Agreement is focused on accelerating access to new molecularly-targeted treatment strategies for these patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1CA186709-03
Application #
9059040
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (J1))
Program Officer
Ivy, S Percy
Project Start
2014-03-13
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
$850,003
Indirect Cost
$216,464
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ben-Ami, Eytan; Barysauskas, Constance M; Solomon, Sarah et al. (2017) Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer 123:3285-3290
Davids, Matthew S; Kim, Haesook T; Bachireddy, Pavan et al. (2016) Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med 375:143-53
LoRusso, Patricia M; Li, Jing; Burger, Angelika et al. (2016) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res 22:3227-37
Friedman, Adam A; Letai, Anthony; Fisher, David E et al. (2015) Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 15:747-56
Konstantinopoulos, Panagiotis A; Ceccaldi, Raphael; Shapiro, Geoffrey I et al. (2015) Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov 5:1137-54
Lee, Jung-Min; Trepel, Jane B; Choyke, Peter et al. (2015) CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovar Front Oncol 5:123
Frederick, Dennie T; Salas Fragomeni, Roberto A; Schalck, Aislyn et al. (2014) Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 9:e101286
Liu, Joyce F; Barry, William T; Birrer, Michael et al. (2014) Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15:1207-14
Corcoran, Ryan B; Cheng, Katherine A; Hata, Aaron N et al. (2013) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23:121-8
Liu, Joyce F; Tolaney, Sara M; Birrer, Michael et al. (2013) A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49:2972-8

Showing the most recent 10 out of 12 publications